The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs.

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Pharmacoresistance to antiepileptic drugs (AEDs) is a barrier to seizure freedom for many persons with epilepsy. For nearly two decades, pharmacoresistance has been framed in terms of factors affecting the access of AEDs to their molecular targets in the brain or the actions of the drugs on these targets. Shortcomings in this prevailing view led to the formulation of the intrinsic severity hypothesis of pharmacoresistance to AEDs, which is based on the recognition that there are neurobiologic factors that confer phenotypic variation among individuals with etiologically similar forms of epilepsy and postulates that more severe epilepsy is more difficult to treat with AEDs. In recent years, progress has been made identifying potential genetic mechanisms of variation in epilepsy severity, including subclinical mutations in ion channels that increase or reduce epilepsy severity in mice. Efforts are underway to identify clinically important genetic modifiers. If it can be demonstrated that such severity factors play a role in pharmacoresistance, treatments could be devised to reverse severity mechanisms. By overcoming pharmacoresistance, this new approach to epilepsy therapy may allow drug refractory patients to achieve seizure freedom without side effects. Wiley Periodicals, Inc.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
JournalEpilepsia
Volume54 Suppl 2
StatePublished - May 2013

Fingerprint

Anticonvulsants
Epilepsy
Seizures
Ion Channels
Pharmaceutical Preparations
Mutation
Brain
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs. / Rogawski, Michael A.

In: Epilepsia, Vol. 54 Suppl 2, 05.2013, p. 33-40.

Research output: Contribution to journalArticle

@article{8ad0243f23eb4cb08ccda8f70fe25cc3,
title = "The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs.",
abstract = "Pharmacoresistance to antiepileptic drugs (AEDs) is a barrier to seizure freedom for many persons with epilepsy. For nearly two decades, pharmacoresistance has been framed in terms of factors affecting the access of AEDs to their molecular targets in the brain or the actions of the drugs on these targets. Shortcomings in this prevailing view led to the formulation of the intrinsic severity hypothesis of pharmacoresistance to AEDs, which is based on the recognition that there are neurobiologic factors that confer phenotypic variation among individuals with etiologically similar forms of epilepsy and postulates that more severe epilepsy is more difficult to treat with AEDs. In recent years, progress has been made identifying potential genetic mechanisms of variation in epilepsy severity, including subclinical mutations in ion channels that increase or reduce epilepsy severity in mice. Efforts are underway to identify clinically important genetic modifiers. If it can be demonstrated that such severity factors play a role in pharmacoresistance, treatments could be devised to reverse severity mechanisms. By overcoming pharmacoresistance, this new approach to epilepsy therapy may allow drug refractory patients to achieve seizure freedom without side effects. Wiley Periodicals, Inc.",
author = "Rogawski, {Michael A}",
year = "2013",
month = "5",
language = "English (US)",
volume = "54 Suppl 2",
pages = "33--40",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The intrinsic severity hypothesis of pharmacoresistance to antiepileptic drugs.

AU - Rogawski, Michael A

PY - 2013/5

Y1 - 2013/5

N2 - Pharmacoresistance to antiepileptic drugs (AEDs) is a barrier to seizure freedom for many persons with epilepsy. For nearly two decades, pharmacoresistance has been framed in terms of factors affecting the access of AEDs to their molecular targets in the brain or the actions of the drugs on these targets. Shortcomings in this prevailing view led to the formulation of the intrinsic severity hypothesis of pharmacoresistance to AEDs, which is based on the recognition that there are neurobiologic factors that confer phenotypic variation among individuals with etiologically similar forms of epilepsy and postulates that more severe epilepsy is more difficult to treat with AEDs. In recent years, progress has been made identifying potential genetic mechanisms of variation in epilepsy severity, including subclinical mutations in ion channels that increase or reduce epilepsy severity in mice. Efforts are underway to identify clinically important genetic modifiers. If it can be demonstrated that such severity factors play a role in pharmacoresistance, treatments could be devised to reverse severity mechanisms. By overcoming pharmacoresistance, this new approach to epilepsy therapy may allow drug refractory patients to achieve seizure freedom without side effects. Wiley Periodicals, Inc.

AB - Pharmacoresistance to antiepileptic drugs (AEDs) is a barrier to seizure freedom for many persons with epilepsy. For nearly two decades, pharmacoresistance has been framed in terms of factors affecting the access of AEDs to their molecular targets in the brain or the actions of the drugs on these targets. Shortcomings in this prevailing view led to the formulation of the intrinsic severity hypothesis of pharmacoresistance to AEDs, which is based on the recognition that there are neurobiologic factors that confer phenotypic variation among individuals with etiologically similar forms of epilepsy and postulates that more severe epilepsy is more difficult to treat with AEDs. In recent years, progress has been made identifying potential genetic mechanisms of variation in epilepsy severity, including subclinical mutations in ion channels that increase or reduce epilepsy severity in mice. Efforts are underway to identify clinically important genetic modifiers. If it can be demonstrated that such severity factors play a role in pharmacoresistance, treatments could be devised to reverse severity mechanisms. By overcoming pharmacoresistance, this new approach to epilepsy therapy may allow drug refractory patients to achieve seizure freedom without side effects. Wiley Periodicals, Inc.

UR - http://www.scopus.com/inward/record.url?scp=84880326639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880326639&partnerID=8YFLogxK

M3 - Article

C2 - 23646969

AN - SCOPUS:84880326639

VL - 54 Suppl 2

SP - 33

EP - 40

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

ER -